An Observational Post-Authorization Safety Surveillance (PASS) Study of Sycrest (Asenapine) Among Patients Aged 18 and Older Diagnosed With Bipolar Disorder.
Phase of Trial: Phase IV
Latest Information Update: 10 Jan 2018
At a glance
- Drugs Asenapine (Primary) ; Olanzapine; Risperidone
- Indications Bipolar disorders; Schizophrenia
- Focus Adverse reactions
- Sponsors Merck Sharp & Dohme
- 28 Dec 2017 Status changed from recruiting to completed.
- 09 Nov 2017 Planned End Date changed from 31 Oct 2017 to 18 Dec 2017.
- 09 Nov 2017 Planned primary completion date changed from 31 Oct 2017 to 18 Dec 2017.